scholarly journals Optimizing Insulin Glargine Plus One Injection of Insulin Glulisine in Type 2 Diabetes in the ELEONOR Study: Similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfaction

Diabetes Care ◽  
2011 ◽  
Vol 34 (12) ◽  
pp. 2524-2526 ◽  
Author(s):  
A. Nicolucci ◽  
S. Del Prato ◽  
G. Vespasiani ◽  
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Health Status ◽  
Insulin Glargine ◽  
Treatment Satisfaction ◽  
Functional Health ◽  
Functional Health Status ◽  
Self Monitoring ◽  
Insulin Glulisine

scholarly journals Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: A pilot, multicentre, randomised controlled trial

2019 ◽  
Vol 16 (4) ◽  
pp. 385-395 ◽  
Author(s):  
Ramzi A Ajjan ◽  
Neil Jackson ◽  
Scott A Thomson
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Secondary Care ◽  
Treatment Satisfaction ◽  
Glucose Monitoring ◽  
Self Monitoring ◽  
Flash Glucose Monitoring ◽  
Time In Range ◽  
Diabetes Patients

Aim: Analyse the effects of professional flash glucose monitoring system (FreeStyle Libre Pro™) on glycaemic control in insulin-treated type 2 diabetes. Methods: Primary (n = 17) and secondary care centres (n = 5) randomised 148 type 2 diabetes patients into three groups: (A) self-monitoring of blood glucose (n = 52), (B) self-monitoring of blood glucose and two Libre Pro sensor wears (n = 46) or (C) self-monitoring of blood glucose and four sensor wears (n = 50). Primary endpoint was time in range (glucose 3.9–10 mmol/L) within group C comparing baseline with days 172–187. Predefined secondary endpoints included HbA1c, hypoglycaemia and quality of life measures analysed within and between groups (clinicaltrials.gov, NCT02434315). Results: In group C, time in range in the first 14 days (baseline) and days 172–187 was similar at 15.0 ± 5.0 and 14.1 ± 4.7 h/day (mean ± SD), respectively, (p = 0.1589). In contrast, HbA1c reduced from baseline to study end within group C by 4.9 ± 8.8 mmol/mol (0.44% ± 0.81%; p = 0.0003). HbA1c was also lower in group C compared with A at study end by 5.4 ± 1.79 mmol/mol (0.48% ± 0.16%; p = 0.0041, adjusted mean ± SE), without increased time in hypoglycaemia ( p = 0.1795). Treatment satisfaction scores improved in group C compared with A ( p = 0.0225) and no device-related serious adverse events were reported. Conclusions: Libre Pro can improve HbA1c and treatment satisfaction without increasing hypoglycaemic exposure in insulin-treated type 2 diabetes individuals managed in primary/secondary care centres.

scholarly journals Real-time continuous glucose monitoring versus self-monitoring of blood glucose in adults with insulin-treated type 2 diabetes: a protocol for a randomised controlled single-centre trial

BMJ Open ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. e040648
Author(s):  
Nanna Lind ◽  
Dorte Lindqvist Hansen ◽  
Signe Sætre Rasmussen ◽  
Kirsten Nørgaard
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Peer Support ◽  
Continuous Glucose Monitoring ◽  
Data Protection ◽  
Treatment Options ◽  
Glucose Monitoring ◽  
Single Centre ◽  
Self Monitoring

IntroductionMedical treatment options for type 2 diabetes (T2D) have increased over the last decade and enhance the possibility of individualised treatment strategies where insulin is still one of them. In spite of the advancements in treatment options, less than one-third of the population with T2D obtain their optimal glycaemic goal. In persons with type 1 diabetes, continuous glucose monitoring (CGM) has shown to be the most important driver for improvement in glycaemic control, even more than insulin-pump therapy. The use of technology in T2D has only been investigated in few studies.The overall objective of the research study is to examine the effectiveness of the use of CGM versus self-monitoring of blood glucose (SMBG) in persons with insulin-treated T2D on glycaemic variables and patient-reported outcomes on treatment satisfaction, health behaviour and well-being. The independent effect of peer support will also be studied.Methods and analysisThe study is a single centre, prospective, randomised, open-labelled, three-armed study with the randomisation 2:1:2 in group A with CGM, group B with CGM and peer support, and group C as a control group with SMBG. The participants receive a training course unique for the allocation group. The study runs for 12 months and includes 100 adult participants with insulin-treated T2D, treated at the outpatient clinic at Steno Diabetes Center Copenhagen. Primary outcome is difference in change in time in range. Recruitment begins in August 2020 and ends in July 2021. Final 12-month follow-up is anticipated to be in August 2022.Ethics and disseminationThe study will be carried out in accordance with the Helsinki Declaration and is approved by the Scientific Ethics Committee of the Capital Region (H-20000843). Data collection and handling will be performed in accordance with the General Data Protection Regulation and is approved by the Danish Data Protection Agency (J-2020-100). Dissemination will be in international peer-reviewed journals, conferences and a plain-language summary for participants.Trial registration numberClinicalTrials.gov Registry (NCT04331444).Protocol versionV.3, 11 December 2020.

Addressing Schemes of Self-Monitoring of Blood Glucose in Type 2 Diabetes: A European Perspective and Expert Recommendation

2011 ◽  
Vol 13 (9) ◽  
pp. 959-965 ◽  
Author(s):  
Oliver Schnell ◽  
Hasan Alawi ◽  
Tadej Battelino ◽  
Antonio Ceriello ◽  
Peter Diem ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
European Perspective ◽  
Self Monitoring ◽  
Expert Recommendation

scholarly journals Self-Monitoring of Blood Glucose in Type 2 Diabetes.

2008 ◽  
Vol 32 (4) ◽  
pp. 319
Author(s):  
Bernadette M. Gatien ◽  
Diana Lawlor ◽  
Ingrid Sketris ◽  
Ehud Ur ◽  
Michael Vallis
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Self Monitoring
Sign in / Sign up

Export Citation Format

Share Document